Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers
- PMID: 27863400
- PMCID: PMC5352059
- DOI: 10.18632/oncotarget.13346
Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers
Abstract
Lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) are the two major subtypes of lung cancer, with LUSC exhibits faster progression rate than LUAD. To investigate the roles of immune-response related genes (IRGs) in lung cancer progression, we used LUAD and LUSC samples at different cancer progression stages, and identified that the expression profiles of IRGs could serve as a better classification marker for cancerous tissues of both LUAD and LUSC. We found that the expression changes of IRGs were different between LUAD and LUSC. Cell cycle promoting genes, including KIFs and proteasomes, showed faster up-regulation in LUSC, whereas immune response promoting genes, including MHC molecules and chemokines, were more rapidly repressed in LUSC. Comparative pathway analysis revealed that members of the Toll-like receptor and T cell receptor signaling pathways exhibited diverged expression changes between LUAD and LUSC, especially at the early cancer stages. Our results revealed the difference of LUAD and LUSC from the immune response point of view, and provided new clues for the differential treatment of LUAD and LUSC.
Keywords: LUAD; LUSC; cancer progression rate; expression features; immune-response related genes.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures






Similar articles
-
Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.Front Endocrinol (Lausanne). 2021 Oct 21;12:755805. doi: 10.3389/fendo.2021.755805. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34745015 Free PMC article.
-
Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data.Mol Med Rep. 2017 Jul;16(1):609-616. doi: 10.3892/mmr.2017.6629. Epub 2017 May 25. Mol Med Rep. 2017. PMID: 28560415 Free PMC article.
-
System analysis of FHIT in LUAD and LUSC: The expression, prognosis, gene regulation network, and regulation targets.Int J Biol Markers. 2022 Jun;37(2):158-169. doi: 10.1177/03936155221084056. Epub 2022 Mar 7. Int J Biol Markers. 2022. PMID: 35254116
-
The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.Anticancer Agents Med Chem. 2022;22(2):223-238. doi: 10.2174/1871520621666210708115406. Anticancer Agents Med Chem. 2022. PMID: 34238200 Review.
-
Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy.Genes Dis. 2024 Jul 11;12(3):101374. doi: 10.1016/j.gendis.2024.101374. eCollection 2025 May. Genes Dis. 2024. PMID: 40083325 Free PMC article. Review.
Cited by
-
Isorhamnetin Enhances the Radiosensitivity of A549 Cells Through Interleukin-13 and the NF-κB Signaling Pathway.Front Pharmacol. 2021 Jan 25;11:610772. doi: 10.3389/fphar.2020.610772. eCollection 2020. Front Pharmacol. 2021. PMID: 33569004 Free PMC article.
-
Comprehensive analysis of the significance of METTL7A gene in the prognosis of lung adenocarcinoma.Front Oncol. 2022 Dec 23;12:1071100. doi: 10.3389/fonc.2022.1071100. eCollection 2022. Front Oncol. 2022. PMID: 36620541 Free PMC article.
-
FANCI Cooperates with IMPDH2 to Promote Lung Adenocarcinoma Tumor Growth via a MEK/ERK/MMPs Pathway.Onco Targets Ther. 2020 Jan 15;13:451-463. doi: 10.2147/OTT.S230333. eCollection 2020. Onco Targets Ther. 2020. PMID: 32021289 Free PMC article.
-
Target genes of N6-methyladenosine regulatory protein ALKBH5 are associated with prognosis of patients with lung adenocarcinoma.J Thorac Dis. 2023 Jun 30;15(6):3228-3236. doi: 10.21037/jtd-22-1464. Epub 2023 Jun 25. J Thorac Dis. 2023. PMID: 37426138 Free PMC article.
-
In silico prediction of COVID-19 cytokine storm in lung cancer types.Biochem Biophys Rep. 2022 Dec;32:101350. doi: 10.1016/j.bbrep.2022.101350. Epub 2022 Sep 22. Biochem Biophys Rep. 2022. PMID: 36164562 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015;65:5–29. - PubMed
-
- Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA: a cancer journal for clinicians. 2016;66:115–132. - PubMed
-
- Detterbeck FC, Boffa DJ, Tanoue LT. The New Lung Cancer Staging System. Chest. 2009;136:260–271. - PubMed
-
- Subramanian J, Govindan R. Lung cancer in never smokers: a review. Journal of clinical oncology. 2007;25:561–570. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials